Author(s)

Kamel El-Reshaid^1*, Shaikha Al-Bader², Hossameldin Tawfik Sallam²

¹Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait city, Kuwait.
²Department of Medicine, Nephrology Unit, Amiri Hospital, Ministry of Health, Kuwait city, Kuwait.

Management of steroid-resistant minimal change disease remains elusive with international guidelines suggesting high-dose corticosteroids and/or Calcineurin inhibitors for months similar to those with refractory idiopathic FSGS. Unfortunately, with such approach, the overall remission rates were 47% - 66%. Moreover, complete remission rates were 32% - 47% and partial remission ones were 19% - 29%. Those limited options of treatment and their poor outcomes led us to conduct the present study to assess the efficacy and safety of a new combined drug-therapy at induction and subsequent maintenance of such disease. The regimen consisted of an initial induction phase of 3-month Prednisone, Calcineurin-inhibitor, Mycophenolate and ACEI/ARB. The latter was followed by a maintenance phase of minimal dose Prednisone and nearly 1/2 the induction dose of Calcineurin inhibitors to decrease their long-term side effects. The results were satisfactory with 14 of the 22 patients, had complete remission. Moreover, 5 patients manifested partial remission and only 3 did not respond. Creatinine clearance was maintained in patients with complete remission yet, was mildly reduced in the partial and non-responsive ones. The safety and efficacy of such new combined drug-therapy provide new tool and future prospective in management of such relentless disease.

ACEI, ARB, Calcineurin Inhibitors, Cyclosporine A, Minimal Change Disease, Mycophenolate, Nephrotic Syndrome, Prednisone, Tacrolimus

El-Reshaid, K. , Al-Bader, S. and Sallam, H. (2022) The Beneficial Effect of Combination of Mycophenolate with Low-Dose Corticosteroids and Calcineurin-Inhibitor as Well as Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Blocker in Induction and Maintenance of Remission in Corticosteroid- and Rituximab-Resistant Minimal Change Nephrotic Syndrome in Adults. Open Journal of Nephrology, 12, 15-22. doi: 10.4236/ojneph.2022.121002.